🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Sandra J. Casak

United States Food and Drug Administration

ORCID: 0000-0001-5988-3985

Also affiliated with Center for Drug Evaluation and Research

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2 -Positive RAS Wild-Type Colorectal Cancer”.

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2 -Positive RAS Wild-Type Colorectal Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1041
N/A
1.1DataRank · unranked
38 citations

M. Naomi Horiba, Mengdie Yuan, Joyce Cheng, Steven J. Lemery, Yuan Li Shen +10 more

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4462
N/A
0.626DataRank · unranked
64 citations

Shan Pradhan, Lola A. Fashoyin‐Aje, Yi Ren, Yuan-Li Shen, Yuan Xu +12 more

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0617
N/A
0DataRank · unranked
10 citations

Sandra J. Casak, Pallavi S. Mishra‐Kalyani, Pourab Roy, Julia A. Beaver, Richard Pazdur +4 more

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0557
N/A
0DataRank · unranked
180 citations

Leigh Marcus, Lola A. Fashoyin‐Aje, Sirisha L. Mushti, Joyce Cheng, Yuan Li Shen +8 more

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1042
N/A
0DataRank · unranked
21 citations

Sandra J. Casak, Sirisha L. Mushti, Joyce Cheng, Sriram Subramaniam, Hong Zhao +15 more

FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0281
N/A
0DataRank · unranked
25 citations

Sandra J. Casak, Sirisha L. Mushti, Joyce Cheng, Brian J. Christmas, Matthew D. Thompson +16 more

FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0517
N/A
0DataRank · unranked
23 citations

Vaibhav Kumar, Chi Song, Mengdie Yuan, Anup Amatya, Joyce Cheng +9 more